These results suggest that BRCA1 exon 11 mutations may not play a critical role in the oncologic outcomes of ovarian cancer compared to non-BRCA1 exon 11 mutations, but the heterogeneity in PFS warrants cautious interpretation. The gene discussed is BRCA1; the disease is ovarian cancer.